Understanding the research landscape of over-the-counter herbal products, dietary supplements, and medications evaluated for depressive symptoms in adults: a scoping review
Forschungslandschaft zu frei verkäuflichen pflanzlichen Produkten, Nahrungsergänzungsmitteln und Medikamenten bei depressiven Symptomen: Scoping-Review
Frontiers in Pharmacology · 15.07.2025 · 16
DOI: 10.3389/fphar.2025.1609605 ↗Auf einen Blick
Das Scoping-Review beschreibt 209 RCTs zu OTC-Produkten bei depressiven Symptomen bei Erwachsenen 18–60 Jahre. Die größte Evidenz lag für Omega-3, Johanniskraut, Safran, Probiotika und Vitamin D vor.
Fragestellung
Wie groß und wie beschaffen ist die Evidenz zu frei verkäuflichen Produkten bei Depression bei Erwachsenen 18–60 Jahre, und welche Produkte sollten weiter untersucht werden?
Methode
Scoping-Review nach Joanna Briggs Institute; Suche in MEDLINE, Embase, PsycINFO, AMED und CENTRAL von Beginn bis Dezember 2022; eingeschlossen wurden RCTs zu OTC-Produkten bei Symptomen oder Diagnose einer Depression.
Ergebnisse
23.933 Treffer, 1.367 Volltexte gescreent, 209 Studien eingeschlossen. Die meiste Evidenz gab es für Omega-3, Johanniskraut, Safran, Probiotika und Vitamin D. Für 41 Produkte gab es nur Einzelstudien.
Schlussfolgerung der Autor:innen
Produkte mit begrenzter, aber vielversprechender Evidenz waren Folsäure, Lavendel, Zink, Tryptophan, Rhodiola und Zitronenmelisse. Weitere Forschung zu diesen Produkten sowie zu additiven Effekten und Sicherheit ist nötig.
Kernaussagen
- 209 RCTs zu OTC-Produkten bei depressiven Symptomen
- Meiste Evidenz für Omega-3, Johanniskraut, Safran, Probiotika und Vitamin D
- Weitere Forschung v. a. zu Folsäure, Lavendel, Zink, Tryptophan, Rhodiola, Zitronenmelisse
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.07.2025. Verfasst von Rachael Frost und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Public and Allied Health, Liverpool John Moores University, Liverpool, United Kingdom. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 259 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR School for Primary Care Research.
Themen: Depression
Abstract (Originalsprache)
Background
Over-the-counter (OTC) products such as herbal medical products (HMPs) or dietary supplements are a valued part of preventative and supportive self-care for depressive symptoms, but there is a wide array of products available, with differing levels of clinical evidence. It is unclear what the optimal directions for future research in this field are.
Aim
We aimed to explore the size and nature of the evidence base available for OTC products for depression in adults aged 18–60.
Methods
We carried out a scoping review following Joanna Briggs Institute guidance. We searched MEDLINE, Embase, PsycINFO, AMED, and CENTRAL from inception to December 2022, and 10% of the results were screened by two authors and the remainder by one author. We included randomised controlled trials of products commonly available OTC in multiple countries in participants with symptoms or a diagnosis of depression. Results were narratively summarised by the product and volume of evidence available.
Results
Out of 23,933 records found, we screened 1,367 full texts and included 209 trials. The largest volume of evidence was for omega-3s, St John’s Wort, saffron, probiotics, and vitamin D. Among a range of herbal medical products with promising evidence, those most commonly used and thus warranting further research were lavender, lemon balm, chamomile, and Echium. For 41 products, we found only single trials. Few products presented safety issues, whether used alone or adjunctively with antidepressants.
Conclusion
Products with limited but promising evidence included folic acid, lavender, zinc, tryptophan, Rhodiola, and lemon balm, and future research should focus on these products. There is a need for further evaluation of herbal medical products as adjuncts to antidepressants and for exploring their potential benefits when used adjunctively with psychological therapies to support a more integrative approach. Safety reporting in these trials needs to be further improved. Systematic Review Registration: https://osf.io/rkm57/ .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Public and Allied Health, Liverpool John Moores University, Liverpool, United Kingdom.
- Department of Primary Care and Population Health, University College London, London, United Kingdom.
- Division of Medicine, University College London, London, United Kingdom.
- Medway School of Pharmacy, University of Kent, Kent, United Kingdom.
- Escuela de Medicina, Universidad Cesar Vallejo, Trujillo, Peru.
- UCL School of Pharmacy, University College London, London, United Kingdom.
Förderung
- NIHR School for Primary Care Research
Zitieren
APA
Frost, R., Zamri, A., Mathew, S., Salame, A., Bhanu, C., Bhamra, S. K., Bazo-Alvarez, J. C., Heinrich, M., & Walters, K. (2025). Understanding the research landscape of over-the-counter herbal products, dietary supplements, and medications evaluated for depressive symptoms in adults: a scoping review. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1609605
Vancouver
Frost R, Zamri A, Mathew S, Salame A, Bhanu C, Bhamra SK, et al. Understanding the research landscape of over-the-counter herbal products, dietary supplements, and medications evaluated for depressive symptoms in adults: a scoping review. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1609605
BibTeX
@article{Frost2025,
author = {Frost, Rachael and Zamri, Aiman and Mathew, Silvy and Salame, Adriana and Bhanu, Cini and Bhamra, Sukvinder K and Bazo-Alvarez, Juan Carlos and Heinrich, Michael and Walters, Kate},
title = {Understanding the research landscape of over-the-counter herbal products, dietary supplements, and medications evaluated for depressive symptoms in adults: a scoping review},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1609605}
}
EUVIMED